Global Oncology Academy - Global Oncology Academy

Global Oncology Academy

Global Oncology Academy

Enhance your practice with CME
and tools that focus on the management
and treatment of patients with cancer.

Popular

Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Project Oncology®
Interpreting Perioperative Trial Designs in Resectable NSCLC Research
Charles Turck, PharmD, BCPS, BCCCP; Laura Alder, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Laura Alder, MD
- Christine Bestvina, MD
Turning Cold Tumors Hot With mRNA COVID-19 Vaccines
Turning Cold Tumors Hot With mRNA COVID-19 Vaccines
COVID-19: On The Frontlines
Turning Cold Tumors Hot With mRNA COVID-19 Vaccines
Hallie Blevins, PhD; Marlene Mimi Maeusli, PhD.
- Hallie Blevins, PhD
- Marlene Mimi Maeusli, PhD.
Real-World Strategies for Complex cGVHD Treatment Decisions
Real-World Strategies for Complex cGVHD Treatment Decisions
Project Oncology®
Real-World Strategies for Complex cGVHD Treatment Decisions
Brian P. McDonough, MD, FAAFP; Doris M. Ponce, MD, MS
- Brian P. McDonough, MD, FAAFP
- Doris M. Ponce, MD, MS
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Project Oncology®
Navigating AKT Inhibitor-Associated Adverse Events in HR+/HER2- Advanced Breast Cancer
Alexandria May, PharmD, BCPS; Adam Brufsky, MD, PhD
- Alexandria May, PharmD, BCPS
- Adam Brufsky, MD, PhD
Addressing Barriers to CAR T Referral in R/R LBCL
Addressing Barriers to CAR T Referral in R/R LBCL
Project Oncology®
Addressing Barriers to CAR T Referral in R/R LBCL
Steve Jackson, PharmD; Matthew J. Matasar, MD
- Steve Jackson, PharmD
- Matthew J. Matasar, MD
- Tycel Phillips, MD
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Project Oncology®
Choosing Between Neoadjuvant and Perioperative Strategies in NSCLC
Steve Jackson, PharmD; Raghava Reddy Induru, MD
- Steve Jackson, PharmD
- Raghava Reddy Induru, MD
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Clinician's Roundtable
Blood-Based Colorectal Cancer Screening: Where Do We Stand?
Peter Buch, MD, FACG, AGAF, FACP; Aasma Shaukat, MD, MPH
- Peter Buch, MD, FACG, AGAF, FACP
- Aasma Shaukat, MD, MPH
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Project Oncology®
Choosing the Right ARPI in Metastatic Castration-Sensitive Prostate Cancer
Brian P. McDonough, MD, FAAFP; Bilal Siddiqui, MD
- Brian P. McDonough, MD, FAAFP
- Bilal Siddiqui, MD

Medical News

Medical News
BCG Plus Mitomycin Fails to Improve DFS in ANZUP 1301
05/22/2026
Read more
Medical News
Early Postoperative Intake Linked To Complications After GI Cancer Surgery
05/19/2026
Read more
Medical News
Pancreatic Ductal Adenocarcinoma with Autoimmune Pancreatitis
05/18/2026
Read more
Medical News
Surgical Outcomes After Neoadjuvant Pembrolizumab in KEYNOTE-522
05/18/2026
Read more

CME/CE

Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
CME/CE
Redefining Immunotherapy Access: Integrating Subcutaneous Checkpoint Inhibitors Across Solid Tumors
Enriqueta Felip, MD; Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
- Enriqueta Felip, MD
- Kristi Orbaugh, MSN, RNP, AOCN
0.25 credits
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
MinuteCE®
HER2+ Breast Cancer With Brain Metastases: Rethinking First-Line Treatment in the ADC Era
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
MinuteCE®
Sequencing Systemic and Local Therapy in HER2-Overexpressing Metastatic NSCLC 
Benjamin Levy, MD; Melin Khandekar, MD, PhD
1.00 program credit
- Benjamin Levy, MD
- Melin Khandekar, MD, PhD
1.00 program credit
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
MinuteCE®
First-Line Management of HR+/HER2-Low Breast Cancer With Brain Metastases
Barbara O'Brien, MD; Nadia Harbeck, MD, PhD
1.00 program credit
- Barbara O'Brien, MD
- Nadia Harbeck, MD, PhD
1.00 program credit

Clinical Practice

Emerging Therapeutic Strategies in Metastatic NSCLC
Emerging Therapeutic Strategies in Metastatic NSCLC
Project Oncology®
Emerging Therapeutic Strategies in Metastatic NSCLC
Brian P. McDonough, MD, FAAFP; Urs Weber, MD
- Brian P. McDonough, MD, FAAFP
- Urs Weber, MD
Optimizing Multidisciplinary Care in Perioperative NSCLC
Optimizing Multidisciplinary Care in Perioperative NSCLC
Project Oncology®
Optimizing Multidisciplinary Care in Perioperative NSCLC
Steve Jackson, PharmD; David Tom Cooke, MD, FACS
- Steve Jackson, PharmD
- David Tom Cooke, MD, FACS
- Joshua Reuss, MD
Epic Aura for CRC Screening: A Real-World Perspective
Epic Aura for CRC Screening: A Real-World Perspective
Clinician's Roundtable
Epic Aura for CRC Screening: A Real-World Perspective
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Improving CRC Screening Conversations in Primary Care
Improving CRC Screening Conversations in Primary Care
Clinician's Roundtable
Improving CRC Screening Conversations in Primary Care
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA

Programs

Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Project Oncology®
Managing AKT Inhibitor-Associated AEs in HR+/HER2- Advanced Breast Cancer
Charles Turck, PharmD, BCPS, BCCCP; Neil M. Iyengar, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Neil M. Iyengar, MD
- Sarah H. Donahue, MPH, NP
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
CME/CE
Improving Quality Care Across the Spectrum of HER2 Expression in HR+ Metastatic Breast Cancers: Practice Changes to Improve Care
Joseph Kim, MD, MPH, MBA, FACHE; Samir Dalia, MD
0.25 credits
- Joseph Kim, MD, MPH, MBA, FACHE
- Samir Dalia, MD
- Christopher Jurief
0.25 credits
Improving CRC Screening Workflows: A PCP's Recommendations
Improving CRC Screening Workflows: A PCP's Recommendations
Clinician's Roundtable
Improving CRC Screening Workflows: A PCP's Recommendations
Natalia Usoltseva MD, FACP, MHA
- Natalia Usoltseva MD, FACP, MHA
Brain Metastases Management: From Detection to Multidisciplinary Care
Brain Metastases Management: From Detection to Multidisciplinary Care
MinuteCE®
Brain Metastases Management: From Detection to Multidisciplinary Care
Barbara O'Brien, MD
1.00 program credit
- Barbara O'Brien, MD
1.00 program credit